Cordlife Group Limited
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic tes… Read more
Cordlife Group Limited (CLIFF) - Net Assets
Latest net assets as of September 2025: $109.69 Million USD
Based on the latest financial reports, Cordlife Group Limited (CLIFF) has net assets worth $109.69 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($207.10 Million) and total liabilities ($97.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $109.69 Million |
| % of Total Assets | 52.96% |
| Annual Growth Rate | 7.97% |
| 5-Year Change | 17.72% |
| 10-Year Change | -10.62% |
| Growth Volatility | 30.27 |
Cordlife Group Limited - Net Assets Trend (2010–2024)
This chart illustrates how Cordlife Group Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cordlife Group Limited (2010–2024)
The table below shows the annual net assets of Cordlife Group Limited from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $118.66 Million | -12.53% |
| 2023-12-31 | $135.65 Million | +0.98% |
| 2022-12-31 | $134.33 Million | +32.60% |
| 2021-12-31 | $101.30 Million | +0.50% |
| 2020-12-31 | $100.80 Million | +4.85% |
| 2019-12-31 | $96.14 Million | -22.32% |
| 2018-12-31 | $123.76 Million | +1.87% |
| 2017-12-31 | $121.49 Million | -3.06% |
| 2016-12-31 | $125.33 Million | -5.59% |
| 2015-12-31 | $132.75 Million | +10.38% |
| 2014-12-31 | $120.27 Million | -14.88% |
| 2013-12-31 | $141.29 Million | +82.16% |
| 2012-12-31 | $77.56 Million | +9.00% |
| 2011-12-31 | $71.16 Million | +75.47% |
| 2010-12-31 | $40.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cordlife Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 235.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $56.83 Million | 47.99% |
| Common Stock | $94.47 Million | 79.78% |
| Total Equity | $118.41 Million | 100.00% |
Cordlife Group Limited Competitors by Market Cap
The table below lists competitors of Cordlife Group Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
REVOLVE RENEW.POWER CORP.
F:PM7
|
$5.87 Million |
|
PreveCeutical Medical Inc
OTCQB:PRVCF
|
$5.87 Million |
|
Pan American Energy Corp
OTCQB:PAANF
|
$5.87 Million |
|
AVENSIA AB SK -15
F:5IY
|
$5.87 Million |
|
Xelpmoc Design And Tech Limited
NSE:XELPMOC
|
$5.87 Million |
|
Jiangsu Zitian Media Technology Co Ltd
SHE:300280
|
$5.87 Million |
|
Nextleaf Solutions Ltd
OTCQB:OILFF
|
$5.86 Million |
|
Sea & Air Freight International
VN:SFI
|
$5.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cordlife Group Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 135,334,000 to 118,406,000, a change of -16,928,000 (-12.5%).
- Net loss of 18,686,000 reduced equity.
- Dividend payments of 74,000 reduced retained earnings.
- Other comprehensive income increased equity by 22,453,000.
- Other factors decreased equity by 20,621,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.69 Million | -15.78% |
| Dividends Paid | $74.00K | -0.06% |
| Other Comprehensive Income | $22.45 Million | +18.96% |
| Other Changes | $-20.62 Million | -17.42% |
| Total Change | $- | -12.51% |
Book Value vs Market Value Analysis
This analysis compares Cordlife Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.27x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.46x to 0.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $0.27 | $0.12 | x |
| 2011-12-31 | $0.41 | $0.12 | x |
| 2012-12-31 | $0.33 | $0.12 | x |
| 2013-12-31 | $0.55 | $0.12 | x |
| 2014-12-31 | $0.46 | $0.12 | x |
| 2015-12-31 | $0.50 | $0.12 | x |
| 2016-12-31 | $0.48 | $0.12 | x |
| 2017-12-31 | $0.49 | $0.12 | x |
| 2018-12-31 | $0.49 | $0.12 | x |
| 2019-12-31 | $0.38 | $0.12 | x |
| 2020-12-31 | $0.52 | $0.12 | x |
| 2021-12-31 | $0.53 | $0.12 | x |
| 2022-12-31 | $0.52 | $0.12 | x |
| 2023-12-31 | $0.53 | $0.12 | x |
| 2024-12-31 | $0.46 | $0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cordlife Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -67.11%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.83x
- Recent ROE (-15.78%) is below the historical average (7.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 20.90% | 33.02% | 0.46x | 1.37x | $4.42 Million |
| 2011 | 9.73% | 22.88% | 0.34x | 1.27x | $-189.90K |
| 2012 | 17.37% | 38.86% | 0.29x | 1.55x | $5.72 Million |
| 2013 | 21.57% | 62.18% | 0.26x | 1.35x | $16.37 Million |
| 2014 | 19.99% | 56.37% | 0.17x | 2.05x | $12.05 Million |
| 2015 | 9.43% | 20.68% | 0.22x | 2.07x | $-739.90K |
| 2016 | -2.05% | -4.29% | 0.30x | 1.59x | $-15.09 Million |
| 2017 | 2.61% | 4.79% | 0.31x | 1.74x | $-9.24 Million |
| 2018 | 1.44% | 2.94% | 0.28x | 1.72x | $-10.59 Million |
| 2019 | 5.01% | 10.51% | 0.27x | 1.74x | $-4.79 Million |
| 2020 | 4.92% | 11.10% | 0.33x | 1.33x | $-6.76 Million |
| 2021 | 4.50% | 10.83% | 0.33x | 1.27x | $-7.51 Million |
| 2022 | 3.65% | 8.86% | 0.24x | 1.70x | $-8.52 Million |
| 2023 | 2.60% | 6.32% | 0.24x | 1.69x | $-10.01 Million |
| 2024 | -15.78% | -67.11% | 0.13x | 1.83x | $-30.53 Million |
Industry Comparison
This section compares Cordlife Group Limited's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cordlife Group Limited (CLIFF) | $109.69 Million | 20.90% | 0.89x | $5.87 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |